NCT05966194 - RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer | Biotech Hunter

Enrollment

216

Participants

Timeline

Start Date

April 2, 2024

Primary Completion Date

July 1, 2025

Study Completion Date

October 1, 2025

Conditions

Oral Mucositis

Interventions

DRUG

RRx-001

RRx-001 for injection (4 mg or 8 mg)

RADIATION

Intensity Modulated Radiation Therapy (IMRT)

Intensity Modulated Radiation Therapy of up to 72 Gy

DRUG

Cisplatin for injection 100 mg/m2

Trial Locations (14)

21204

RECRUITING

Sandra and Malcolm Berman Cancer Institute, Baltimore

22908

RECRUITING

University of Virginia, Charlottesville

27834

RECRUITING

East Carolina University School of Medicine, Greenville

33176

RECRUITING

Miami Cancer Institute, Miami

37604

RECRUITING

Ballad Health, Johnson City

43210

RECRUITING

The Ohio State University James Cancer Hospital & Solove Research Institute, Columbus

46845

RECRUITING

Parkview Cancer Institute, Fort Wayne

48109

RECRUITING

University of Michigan, Ann Arbor

60611

RECRUITING

Northwestern University Feinberg School of Medicine, Chicago

71103

RECRUITING

Willis Knighton Cancer Center, Shreveport

75390

RECRUITING

University of Texas Southwestern Medical Center, Dallas

85234

RECRUITING

Banner MD Anderson Cancer Center, Gilbert

85719

RECRUITING

The University of Arizona Cancer Center, Tucson

89502

RECRUITING

Renown Regional Medical Center, Reno